Search clinical trials for: Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin

Total 335 results

Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Zhejiang University

Recruiting

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Colorectal Cancer

China
Hutchmed

Completed

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Lymphoma | Osteosarcoma | Solid Tumor | Ewing Sarcoma | Rhabdomyosarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma

United States
Xuhua Duan

Recruiting

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma

China
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Mismatch Repair Deficiency | Adenocarcinoma of Esophagogastric Junction

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Yu jiren

Not yet recruiting

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Epstein-Barr Virus-Associated Gastric Carcinoma

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
Hutchmed

Not yet recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Sun Yat-sen University
The First Hospital of Nanchang

Not yet recruiting

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Lymphoma Academic Research Organisation
Innate Pharma

Recruiting

Study of Lacutamab in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapse/Recurrence

France, Spain, Belgium, Germany
AIPING ZHOU

Recruiting

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Gastric Cancer Stage III | Gastric Cancer Stage II

China
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
University of California, Irvine

Terminated

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

Carcinoma, Transitional Cell

United States
Sun Yat-sen University

Recruiting

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NK/T Cell Lymphoma Nos

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Assistance Publique - Hôpitaux de Paris

Terminated

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (THYGEMOX)

Thyroid Cancer

France
University Hospital, Montpellier
Federation Francophone de Cancerologie Digestive

Recruiting

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma (GEMOXIA-02)

Cholangiocarcinoma Non-resectable | Non-metastatic

France
Shanghai Zhongshan Hospital

Unknown

Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

China
Zhujiang Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer

China
Air Force Military Medical University, China

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma

China
Lu Wang, MD, PhD

Enrolling by invitation

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Biliary Tract Adenocarcinoma

China
University of Hawaii

Withdrawn

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Metastatic Pancreatic Cancer | ERCC1

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Completed

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (BTC)

Cholangiocarcinoma | Adenocarcinoma of Gallbladder

Taiwan
Samsung Medical Center

Completed

Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma

Unresectable, Metastatic Biliary Tract Carcinoma

Korea, Republic of
University of Zurich

Terminated

Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer

Pancreatic Cancer

France, Switzerland, Belgium, Germany
Zhejiang Cancer Hospital

Unknown

Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
Vejle Hospital

Completed

Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Dorte Nielsen

Completed

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Sun Yat-sen University

Recruiting

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

NK/T Cell Lymphoma Nos

China
RenJi Hospital

Not yet recruiting

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
Peking Union Medical College Hospital

Recruiting

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy

China
German Low Grade Lymphoma Study Group

Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

Indolent Lymphoma

Germany
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Emory University
Sanofi

Terminated

A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Carcinoma, Transitional Cell

France
Sanofi

Completed

Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients (GON)

Non Small Cell Lung Cancer

France

3

Subscribe